

# Olov Wiklund

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7695391/olov-wiklund-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39  
papers

11,085  
citations

30  
h-index

40  
g-index

40  
ext. papers

14,610  
ext. citations

7.6  
avg, IF

5.32  
L-index

#	Paper	IF	Citations
39	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 111-188	9.5	2236
38	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , <b>2016</b> , 37, 2999-3058	9.5	1781
37	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , <b>2017</b> , 38, 2459-2472	9.5	1267
36	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , <b>2015</b> , 36, 1012-22	9.5	770
35	Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. <i>Nature</i> , <b>2002</b> , 417, 750-4	50.4	689
34	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>Atherosclerosis</i> , <b>2016</b> , 253, 281-344	3.1	519
33	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , <b>2015</b> , 36, 2425-37	9.5	430
32	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 655-66	18.1	357
31	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>European Heart Journal</i> , <b>2011</b> , 32, 1074-76	9.5	353
30	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. <i>Gastroenterology</i> , <b>2016</b> , 150, 1219-1230.e6	13.3	347
29	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , <b>2020</b> , 41, 2313-2330	9.5	301
28	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 4077-85	5.6	230
27	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 705-12	13.4	227
26	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , <b>2018</b> , 39, 2526-2539	9.5	156
25	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , <b>2018</b> , 39, 1131-1143	9.5	132
24	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 1006-1033	5.5	124
23	Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. <i>Stroke</i> , <b>1997</b> , 28, 1189-94	6.7	123

22	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , <b>2017</b> , 38, 2245-2255	9.5	105
21	Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. <i>Stroke</i> , <b>2002</b> , 33, 572-7	6.7	104
20	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , <b>2016</b> , 62, 930-46	5.5	104
19	ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. <i>Diabetes</i> , <b>2009</b> , 58, 2018-26	0.9	97
18	Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2001</b> , 21, 269-74	9.4	73
17	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 5212-5222	5.6	71
16	Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2016</b> , 2, 212-7	6.4	65
15	Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1998</b> , 18, 1203-11	9.4	64
14	On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Comments on results from a prospective ultrasound study in patients with familial hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1996</b> , 16, 843-50	9.4	60
13	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, 496-517	5.9	50
12	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , <b>2020</b> , 294, 46-61	3.1	49
11	Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. <i>Clinical Endocrinology</i> , <b>1994</b> , 41, 603-8	3.4	49
10	Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. <i>Atherosclerosis</i> , <b>2014</b> , 233, 83-90	3.1	39
9	Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. <i>Current Cardiology Reports</i> , <b>2013</b> , 15, 397	4.2	25
8	Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 816-823	4.9	24
7	Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. <i>Journal of Clinical Pharmacology</i> , <b>1990</b> , 30, S124-31	2.9	21
6	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2018</b> , 4, 119-127	6.4	11
5	Identification and analysis of macrophage-derived foam cells from human atherosclerotic lesions by using a BockFL3 channel in flow cytometry <b>1997</b> , 29, 155-164		10

4	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , <b>2018</b> , 39, 2600-2601	9.5	9
3	Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 1639-1646	3.9	8
2	High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease. <i>The Application of Clinical Genetics</i> , <b>2019</b> , 12, 71-78	3.1	5
1	German Camejo (1936-2021).. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2022</b> , 42, 241-242	9.4	